Alzheimer’s Therapeutics Market – By Drug Class (Cholinesterase Inhibitors, NMDA, Combination Drugs, Glutamate, MAO), Route of Administration (Oral, Injectable, Transdermal), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 – 2032

Alzheimer’s Therapeutics Market – By Drug Class (Cholinesterase Inhibitors, NMDA, Combination Drugs, Glutamate, MAO), Route of Administration (Oral, Injectable, Transdermal), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 – 2032

Alzheimer’s Therapeutics Market Size

Alzheimer’s Therapeutics Market size was valued at USD 5.8 billion in 2023 and is expected to exhibit growth at a CAGR of 9.8% from 2024 to 2032. High market growth can be attributed to the ongoing advancements in diagnostic technologies, increasing prevalence of Alzheimer’s disease, expanding geriatric population, technological advancements in novel drug delivery system, and growing healthcare expenditure, among other contributing factors.

To get key market trends

  Download Free Sample

Moreover, the most significant driver is the rising prevalence of Alzheimer's disease globally. As the global population ages, the number of people diagnosed with Alzheimer’s disease continues to increase. For instance, according to Alzheimer's Association research published in 2023, an estimated 6.7 million Americans aged 65 and older had Alzheimer's disease, with the figure expected to rise to 13.8 million by 2060. Thus, the risk of Alzheimer’s increases with age, making it more common in the elderly population.

Furthermore, recent advancements in diagnostic technologies have made it easier to diagnose Alzheimer’s disease at an early stage. Improved imaging techniques, biomarkers, and genetic testing have contributed to early detection and intervention, which, in turn, drives the demand for therapeutics.

Alzheimer’s therapeutics refers to the range of treatments and interventions designed to manage, treat, and potentially cure Alzheimer's disease, encompassing pharmacological treatments like cholinesterase inhibitors and NMDA receptor antagonists, emerging therapies such as immunotherapies and gene therapies, as well as non-pharmacological interventions like cognitive and behavioral therapies, lifestyle modifications, and supportive care.

What are the growth opportunities in this market?

 Download Free Sample

Alzheimer’s Therapeutics Market Trends

The Alzheimer’s therapeutics industry is experiencing several notable trends that are shaping its growth and development. Factors such as continuous innovations in drug development, shift towards disease-modifying therapies, growing personalized medicine approaches, and surging need of integrated digital health technologies, among other factors are propelling the industry growth.

• There is a significant shift from symptomatic treatments to disease-modifying therapies (DMTs) that target the underlying causes of Alzheimer’s. These include drugs that aim to reduce amyloid-beta plaques and tau tangles, which are hallmark pathologies of Alzheimer's disease. This trend is driven by the urgent need for treatments that can alter the disease course rather than merely alleviate symptoms.
• Further, there is an increasing focus on non-pharmacological interventions, including cognitive training, lifestyle modifications, and behavioral health therapies. These interventions complement pharmacological treatments and focus on improving overall brain health, delaying disease onset, and enhancing the quality of life for patients, thereby aforementioned factors are expected to drive the market.

Alzheimer’s Therapeutics Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on drug class, the market is classified into cholinesterase inhibitors, NMDA receptor antagonist, combination drugs, glutamate inhibitors, MAO inhibitors, and other drug classes. The cholinesterase inhibitors segment generated the highest revenue of USD 2.6 billion in 2023.

• Cholinesterase inhibitors like donepezil, rivastigmine, and galantamine have a well-documented efficacy and safety profile, which makes them a trusted choice among healthcare providers. Their ability to temporarily improve symptoms of cognitive decline and functional abilities in mild to moderate Alzheimer’s patients underpins their continued use.
• Furthermore, it provides symptomatic relief by enhancing cholinergic neurotransmission, which is compromised in Alzheimer's patients. This symptomatic benefit, although not curative, is crucial for improving the quality of life for patients and is a significant driver for their prescription

Learn more about the key segments shaping this market

 Download Free Sample

Based on route of administration, the Alzheimer’s therapeutics market is classified into oral, injectable, and transdermal patch. The oral segment dominated the market in 2023 with a market share of 58%.

• Oral medications are generally easier to administer than other forms of treatment, such as injections or infusions. This convenience improves patient compliance, as taking a pill is less intrusive and more manageable for daily routines, especially important in the elderly population who may have multiple comorbidities and medications.
• Moreover, oral therapies are non-invasive, avoiding the discomfort and potential complications associated with injectable or intravenous treatments. This non-invasiveness is particularly important for Alzheimer’s patients, who may be more sensitive or anxious about invasive procedures.

Based on distribution channel, the Alzheimer’s therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 8.2 billion by the end of forecast period.
 

• Hospital pharmacies provide centralized management of medications, ensuring that Alzheimer’s patients receive their prescribed drugs accurately and on time. This centralized control helps in maintaining consistent medication regimens, which is crucial for managing a chronic condition like Alzheimer’s.
• Furthermore, these pharmacies are well-versed in the complexities of Alzheimer’s therapeutics, including drug interactions, side effects, and optimal dosing. Their expertise ensures that patients receive the most appropriate and effective medications, improving treatment outcomes, leading to segment growth.

Looking for region specific data?

 Download Free Sample

North America Alzheimer’s therapeutics market accounted for USD 2.2 billion market revenue in 2023 and is anticipated to grow during the forecast period.

• North America, particularly the U.S., has a significant and growing number of Alzheimer's disease cases. The aging population, with a high proportion of individuals over 65, contributes to the increasing prevalence of the disease, driving demand for effective therapeutics.
• Moreover, the region boasts a highly developed healthcare infrastructure, including state-of-the-art hospitals, research facilities, and specialized Alzheimer’s care centers. This advanced infrastructure supports the development, testing, and delivery of innovative Alzheimer's treatments, leading to regional growth.

Germany Alzheimer’s therapeutics market is projected to grow remarkably in the coming years.

• Germany is home to a strong pharmaceutical and biotechnology industry, with many companies actively involved in the research and development of Alzheimer’s therapeutics. This industry’s strength supports the continuous development and introduction of new treatments.
• Additionally, the country’s government provides significant support and funding for Alzheimer’s research. Initiatives such as the National Dementia Strategy aim to improve research, care, and support for Alzheimer’s patients. Government grants and funding for research projects drive innovation in this field.

Japan holds a dominant position in the Asia Pacific Alzheimer’s therapeutics market.

• Japan has one of the fastest-aging populations in the world. With a high proportion of elderly individuals, the prevalence of Alzheimer’s disease is increasing, driving demand for effective therapeutic solutions. The Japanese government projects that by 2025, around 7 million people in the country will have dementia, a substantial portion of whom will have Alzheimer's disease.
• Moreover, the country has an advanced healthcare system with excellent medical facilities, specialized Alzheimer’s care centers, and a high standard of medical care. This infrastructure supports the diagnosis, treatment, and management of Alzheimer’s disease, contributing to market growth.

Alzheimer’s Therapeutics Market Share

The Alzheimer’s therapeutics industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The market is characterized by significant growth, driven by the increasing prevalence of Alzheimer’s disease, especially among the aging global population.

Market share is dominated by North America and Europe due to their advanced healthcare infrastructure, robust R&D capabilities, and strong regulatory frameworks. Major pharmaceutical companies such as Biogen, Eisai, and Eli Lilly lead in developing innovative treatments, including disease-modifying therapies and symptomatic treatments. Emerging markets in Asia-Pacific, particularly Japan and China, are also witnessing rapid growth due to rising awareness, improved healthcare facilities, and increased government support.

Alzheimer’s Therapeutics Market Companies

Prominent players operating in the Alzheimer’s therapeutics industry include

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca
• Biogen
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• H. Lundbeck A/S
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi
• Sun Pharmaceutical Industries Ltd.

Alzheimer’s Therapeutics Industry News

• In May 2024, Voyager Therapeutics, Inc. has announced that the first participants have been dosed in a Phase 1a single ascending dose (SAD) study of VY-TAU01, an experimental anti-tau antibody created to prevent the spread of pathogenic tau in Alzheimer's disease.
• In April 2024, Acumen Pharmaceuticals signed a partnership agreement with Lonza to manufacture sabirnetug (ACU193), an antibody targeting toxic soluble AβOs for the treatment of Alzheimer's disease. This collaboration has included clinical development and commercialization. As per the agreement, Lonza will manufacture the sabirnetug medicinal ingredient at its next-generation manufacturing facility in Portsmouth, New Hampshire (US), which will be equipped with 2,000L single-use bioreactors.

The Alzheimer’s therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments

Click here to Buy Section of this Report

Market, By Drug Class

• Cholinesterase inhibitors
• NMDA receptor antagonist
• Combination drugs
• Glutamate inhibitors
• MAO inhibitors
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable
• Transdermal patch

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa